Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 5Withdrawn 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × JDQ443 × Clear all
NCT05329623 2025-10-10

A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.

Novartis

Phase 1 Completed
33 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡